^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PD-L1 expression + CD47 expression

    i
    Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule, CD47, CD47 Molecule, Antigenic Surface Determinant Protein OA3, Leukocyte Surface Antigen CD47, IAP, CD47 Antigen (Rh-Related Antigen, Integrin-Associated Signal Transducer), Antigen Identified By Monoclonal Antibody 1D8, Integrin Associated Protein, Rh-Related Antigen, CD47 Glycoprotein, MER6, OA3, Integrin-Associated Signal Transducer, Integrin-Associated Protein, Protein MER6, CD47 Antigen
    Entrez ID:
    29126; 961
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    Glucose Transporter 1-Mediated Transcytosis of Glucosamine-Labeled Liposomal Ceramide Targets Hypoxia Niches and Cancer Stem Cells to Enhance Therapeutic Efficacy. (PubMed, ACS Nano)
    To achieve an ideal therapeutic outcome, we combined treatment of glucosamine-labeled liposomal ceramide with paclitaxel and carboplatin, and we found an excellent synergistic effect, with tumor clearance being noted in three-fourths of the mice. Overall, our findings provide a potential therapeutic strategy for the treatment of cancer.
    Journal • Cancer stem • PD(L)-1 Biomarker • IO biomarker
    |
    CD47 (CD47 Molecule) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    PD-L1 expression • HIF1A expression • PD-L1 expression + CD47 expression • POU5F1 expression
    |
    carboplatin • paclitaxel